This continuing feature updates readers on recent developments in cardiovascular pharmacotherapy. Cardiovascular disease remains the number 1 killer in the United States, and more clinical outcome trials have been conducted in cardiology than in any other field of medicine. Given this rapidly expanding knowledge base, if pharmacists stay current with developments in drug therapy, they can have a significant impact on prevention and treatment.
Get full access to this article
View all access options for this article.
References
1.
NorrisS.L., KansagaraD., Bougatsos, FuR.; US Preventive Services Task Force. Screening adults for type 2 diabetes: a review of the evidence for the US Preventive Services Task Force. Ann Intern Med.2008; 148(11): 855–868.
2.
SelvinE., MarinopoulosS., BerkenblitG.Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med.2004; 141(6): 421–431.
3.
UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet.1998; 352(9131): 837–853.
4.
Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group, Gerstein HC, Miller ME, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med.2008; 358(24): 2545–2559.
5.
ADVANCE Collaborative Group, PatelA., MacMahonS.Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med.2008; 358(24): 2560–2572.
6.
BealsJ.K.VA Diabetes Trial shows that intensive glucose control has little effect on cardiovascular risk. theheart.org. Published June 17, 2008. Accessed June 17, 2008.
7.
NissenS.E., WolskiK.Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med.2007; 356(24): 2457–2471.
8.
Executive Summary.Standards of medical care in diabetes—2008. Diabetes Care.2008; 31(Suppl 1): S5–S11.
9.
SaydahS.H., FradkinJ., CowieC.C.Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA.2004; 291(3): 335–342.
